A randomized, double-blind, placebo-controlled phase II study to evaluate the efficacy and safety of ivarmacitinib (SHR0302) in adult patients with moderate-to-severe alopecia areata-Reference-Cited by-同舟云学术

A randomized, double-blind, placebo-controlled phase II study to evaluate the efficacy and safety of ivarmacitinib (SHR0302) in adult patients with moderate-to-severe alopecia areata

Published:2023-11 Issue:5 Volume:89 Page:911-919
ISSN:0190-9622
Container-title:Journal of the American Academy of Dermatology
language:en
Short-container-title:Journal of the American Academy of Dermatology

Author:

Zhou Cheng,Yang Xiumin,Yang Bin,Yan Guofu,Dong Xiuqin,Ding Yangfeng,Fan Weixin,Li Linfeng,Yang Dingquan,Fang Hong,Ji Chao,Cheng Hao,Zhang Shoumin,Goh Aik Han,Liu Rongjun,Gu Xiaoyu,Weng Zaili,Foley Peter,Sinclair Rodney,Zhang Jianzhong

Publisher

Elsevier BV

Subject

Dermatology

Reference25 articles.

1. Lifetime incidence risk of alopecia areata estimated at 2.1% by Rochester Epidemiology Project, 1990–2009;Mirzoyev;J Invest Dermatol,2014

2. Alopecia areata: review of epidemiology, clinical features, pathogenesis, and new treatment options;Darwin;Int J Trichology,2018

3. Treatment of alopecia areata: an Australian expert consensus statement;Cranwell;Australas J Dermatol,2019

4. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition;Xing;Nat Med,2014

5. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata;Kennedy Crispin;JCI Insight,2016

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Up-and-Coming Drugs for the Treatment of Vitiligo;ANN DERMATOL;2024

2. Novel investigational drugs for alopecia areata and future perspectives;Expert Opinion on Investigational Drugs;2024-05-03

3. Aim to alleviate alopecia areata with newly available agents;Drugs & Therapy Perspectives;2024-05

4. Comparative efficacy and safety of JAK inhibitors in the treatment of moderate-to-severe alopecia areata: a systematic review and network meta-analysis;Frontiers in Pharmacology;2024-04-10

5. Short-Term Cardiovascular Complications in Dermatology Patients Receiving JAK-STAT Inhibitors;JAMA Dermatology;2024-03-01